|
1
|
Shah JP and Lydiatt W: Treatment of cancer
of the head and neck. CA Cancer J Clin. 45:352–368. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Joshi P, Dutta S, Chaturvedi P and Nair S:
Head and neck cancers in developing countries. Rambam Maimonides
Med J. 5:e00092014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khan Z, Tönnies J and Müller S: Smokeless
tobacco and oral cancer in South Asia: A systematic review with
meta-analysis. J Cancer Epidemiol. 2014:3946962014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
National Cancer Control Programme (NCCP),
. Cancer Incidence Data Sri Lanka 2010. (12). NCCP. (Colombo).
1–82. 2016.
|
|
5
|
Amarasinghe HK, Usgodaarachchi US, Johnson
NW, Lalloo R and Warnakulasuriya S: Betel-quid chewing with or
without tobacco is a major risk factor for oral potentially
malignant disorders in Sri Lanka: A case-control study. Oral Oncol.
46:297–301. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
No authors listed, . Sri Lankan
declaration on oral cancer, smokeless tobacco and areca nut -
Towards a society free of oral cancer. Sri Lanka Dental Journal.
45:27–29. 2015.
|
|
7
|
Somatunga LC, Sinha DN, Sumanasekera P,
Galapatti K, Rinchen S, Kahandaliyanage A, Mehta FR and Nishirani
Lanka JD: Smokeless tobacco use in Sri Lanka. Indian J Cancer.
49:357–363. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
World Health Organization - International
Agency for Research on Cancer (IARC), . IARC Monographs on the
Evaluation of Carcinogenic Risks to Humans. 89:IARC. (Lyon). 1–593.
2017.
|
|
9
|
Kreimer AR, Clifford GM, Boyle P and
Franceschi S: Human papillomavirus types in head and neck squamous
cell carcinomas worldwide: A systematic review. Cancer Epidemiol
Biomarkers Prev. 14:467–475. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Deb SP and Deb S: Mutant p53 and MDM2 in
cancer. Springer. 2014. View Article : Google Scholar
|
|
11
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen MB, Wu XY, Yu R, Li C, Wang LQ, Shen
W and Lu PH: P53 status as a predictive biomarker for patients
receiving neoadjuvant radiation-based treatment: A meta-analysis in
rectal cancer. PLoS One. 7:e453882012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu HL, Shao L, Wang Q, Jia T, Li M and
Yang DP: A systematic review of p53 as a biomarker of survival in
patients with osteosarcoma. Tumour Biol. 34:3817–3821. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Greenblatt MS, Bennett WP, Hollstein M and
Harris CC: Mutations in the p53 tumor suppressor gene: Clues to
cancer etiology and molecular pathogenesis. Cancer Res.
54:4855–4878. 1994.PubMed/NCBI
|
|
15
|
Lane DP: On the expression of the p53
protein in human cancer. Mol Biol Rep. 19:23–29. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mitra S, Banerjee S, Misra C, Singh RK,
Roy A, Sengupta A, Panda CK and Roychoudhury S: Interplay between
human papilloma virus infection and p53 gene alterations in head
and neck squamous cell carcinoma of an Indian patient population. J
Clin Pathol. 60:1040–1047. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maruyama H, Yasui T, Ishikawa-Fujiwara T,
Morii E, Yamamoto Y, Yoshii T, Takenaka Y, Nakahara S, Todo T,
Hongyo T and Inohara H: Human papillomavirus and p53 mutations in
head and neck squamous cell carcinoma among Japanese population.
Cancer Sci. 105:409–417. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jayasooriya PR, Kurose K, Terai M,
Sivagnanam K, Siriwardana S, Tilakaratne WM, Tagami J and Takagi M:
Human papillomavirus in oral cancer from Sri Lanka: Prevalence and
relationship with clinico-pathological parameters. Oral Med Pathol.
8:45–50. 2003. View Article : Google Scholar
|
|
19
|
Miller SA, Dykes DD and Polesky HF: A
simple salting out procedure for extracting DNA from human
nucleated cells. Nucleic Acids Res. 16:12151988. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Richards S, Aziz N, Bale S, Bick D, Das S,
Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al:
Standards and guidelines for the interpretation of sequence
variants: A joint consensus recommendation of the American college
of medical genetics and genomics and the association for molecular
pathology. Genet Med. 17:405–424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de Roda Husman AM, Walboomers JM, van den
Brule AJ, Meijer CJ and Snijders PJ: The use of general primers GP5
and GP6 elongated at their 3′ ends with adjacent highly conserved
sequences improves human papillomavirus detection by PCR. J Gen
Virol. 76:1057–1062. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim JS and Kim BW: Esophageal cancer and
head and neck cancer: The earlier, the better. Gut Liver.
9:131–132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bouaoun L, Sonkin D, Ardin M, Hollstein M,
Byrnes G, Zavadil J and Olivier M: TP53 variations in human
cancers: New lessons from the IARC TP53 database and genomics data.
Hum Mutat. 37:865–876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: Lessons from recent developments in the IARC TP53
database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kato S, Han SY, Liu W, Otsuka K, Shibata
H, Kanamaru R and Ishioka C: Understanding the function-structure
and function-mutation relationships of p53 tumor suppressor protein
by high-resolution missense mutation analysis. Proc Natl Acad Sci
USA. 100:8424–8429. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mathe E, Olivier M, Kato S, Ishioka C,
Vaisman I and Hainaut P: Predicting the transactivation activity of
p53 missense mutants using a four-body potential score derived from
Delaunay tessellations. Hum Mutat. 27:163–172. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dumont P, Leu JI, Della Pietra AC III,
George DL and Murphy M: The codon 72 polymorphic variants of p53
have markedly different apoptotic potential. Nat Genet. 33:357–365.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Toyama T, Zhang Z, Nishio M, Hamaguchi M,
Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H and Fujii Y:
Association of TP53 codon 72 polymorphism and the outcome of
adjuvant therapy in breast cancer patients. Breast Cancer Res.
9:R342007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Damin AP, Frazzon AP, Damin DC, Roehe A,
Hermes V, Zettler C and Alexandre CO: Evidence for an association
of TP53 codon 72 polymorphism with breast cancer risk. Cancer
Detect Prev. 30:523–529. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li T, Lu ZM, Guo M, Wu QJ, Chen KN, Xing
HP, Mei Q and Ke Y: p53 codon 72 polymorphism (C/G) and the risk of
human papillomavirus-associated carcinomas in China. Cancer.
95:2571–2576. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fan R, Wu MT, Miller D, Wain JC, Kelsey
KT, Wiencke JK and Christiani DC: The p53 codon 72 polymorphism and
lung cancer risk. Cancer Epidemiol Biomarkers Prev. 9:1037–1042.
2000.PubMed/NCBI
|
|
32
|
Baynes C, Healey CS, Pooley KA, Scollen S,
Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA and Dunning
AM; SEARCH breast cancer study, : Common variants in the ATM,
BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are
unlikely to increase breast cancer risk. Breast Cancer Res.
9:R272007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mabrouk I, Baccouche S, El-Abed R,
Mokdad-Gargouri R, Mosbah A, Saïd S, Daoud J, Frikha M, Jlidi R and
Gargouri A: No evidence of correlation between p53 codon 72
polymorphism and risk of bladder or breast carcinoma in Tunisian
patients. Ann NY Acad Sci. 1010:764–770. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chiba I, Muthumala M, Yamazaki Y, Uz Zaman
A, Iizuka T, Amemiya A, Shibata T, Kashiwazaki H, Sugiura C and
Fukuda H: Characteristics of mutations in the p53 gene of oral
squamous-cell carcinomas associated with betel-quid chewing in Sri
Lanka. Int J Cancer. 77:839–842. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Poeta ML, Manola J, Goldwasser MA,
Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D,
Saunders J, et al: TP53 mutations and survival in squamous-cell
carcinoma of the head and neck. N Engl J Med. 357:2552–2561. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Neskey DM, Osman AA, Ow TJ, Katsonis P,
McDonald T, Hicks SC, Hsu TK, Pickering CR, Ward A, Patel A, et al:
Evolutionary action score of TP53 identifies high-risk mutations
associated with decreased survival and increased distant metastases
in head and neck cancer. Cancer Res. 75:1527–1536. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Reich NC, Oren M and Levine A: Two
distinct mechanisms regulate the levels of a cellular tumor
antigen, p53. Mol Cell Biol. 3:2143–2150. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Blagosklonny MV: Loss of function and p53
protein stabilization. Oncogene. 15:1889–1893. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nagata Y, Anan T, Yoshida T, Mizukami T,
Taya Y, Fujiwara T, Kato H, Saya H and Nakao M: The stabilization
mechanism of mutant-type p53 by impaired ubiquitination: The loss
of wild-type p53 function and the hsp90 association. Oncogene.
18:6037–6049. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vojtĕsek B, Bártek J, Midgley CA and Lane
DP: An immunochemical analysis of the human nuclear phosphoprotein
p53. New monoclonal antibodies and epitope mapping using
recombinant p53. J Immunol Methods. 151:237–244. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Harden ME and Munger K: Human
papillomavirus molecular biology. Mutat Res Rev Mutat Res.
772:3–12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ang KK, Harris J, Wheeler R, Weber R,
Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C,
et al: Human papillomavirus and survival of patients with
oropharyngeal cancer. N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lassen P, Eriksen JG, Hamilton-Dutoit S,
Tramm T, Alsner J and Overgaard J: Effect of HPV-associated
p16INK4A expression on response to radiotherapy and survival in
squamous cell carcinoma of the head and neck. J Clin Oncol.
27:1992–1998. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fakhry C, Westra WH, Li S, Cmelak A, Ridge
JA, Pinto H, Forastiere A and Gillison ML: Improved survival of
patients with human papillomavirus-positive head and neck squamous
cell carcinoma in a prospective clinical trial. J Natl Cancer Inst.
100:261–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dok R and Nuyts S: HPV positive head and
neck cancers: Molecular pathogenesis and evolving treatment
strategies. Cancers (Basel). 8:E412016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Grønhøj Larsen C, Gyldenløve M, Jensen DH,
Therkildsen MH, Kiss K, Norrild B, Konge L and Von Buchwald C:
Correlation between human papillomavirus and p16 overexpression in
oropharyngeal tumours: A systematic review. Br J Cancer.
110:1587–1594. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lewis JS Jr, Thorstad WL, Chernock RD,
Haughey BH, Yip JH, Zhang Q and El-Mofty SK: p16 positive
oropharyngeal squamous cell carcinoma: An entity with a favorable
prognosis regardless of tumor HPV status. Am J Surg Pathol.
34:1088–1096. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Smith EM, Rubenstein LM, Hoffman H, Haugen
TH and Turek LP: Human papillomavirus, p16 and p53 expression
associated with survival of head and neck cancer. Infect Agent
Cancer. 5:42010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Murthy V, Swain M, Teni T, Pawar S, Kalkar
P, Patil A, Chande A, Ghonge S, Laskar SG, Gupta T, et al: Human
papillomavirus/p16 positive head and neck cancer in India:
Prevalence, clinical impact, and influence of tobacco use. Indian J
Cancer. 53:387–393. 2016.PubMed/NCBI
|
|
52
|
Githaiga BK, Muchiri LW and Rogena EA: P16
expression in subsets of head and neck squamous cell carcinoma
reported in Kenyatta National Hospital Nairobi, Kenya. Pathol.
46:S962014. View Article : Google Scholar
|
|
53
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
|
|
54
|
Sritippho T, Pongsiriwet S,
Lertprasertsuke N, Buddhachat K, Sastraruji T and Iamaroon A: p16-a
possible surrogate marker for high-risk human papillomaviruses in
oral cancer? Asian Pac J Cancer Prev. 17:4049–4057. 2016.PubMed/NCBI
|
|
55
|
Storey A, Thomas M, Kalita A, Harwood C,
Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G and
Banks L: Role of a p53 polymorphism in the development of human
papillomavirus-associated cancer. Nature. 393:229–234. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Klug SJ, Wilmotte R, Santos C, Almonte M,
Herrero R, Guerrero I, Caceres E, Peixoto-Guimaraes D, Lenoir G,
Hainaut P, et al: TP53 polymorphism, HPV infection, and risk of
cervical cancer. Cancer Epidemiol Biomarkers Prev. 10:1009–1012.
2001.PubMed/NCBI
|
|
57
|
Andersson S, Rylander E, Strand A,
Sällström J and Wilander E: The significance of p53 codon 72
polymorphism for the development of cervical adenocarcinomas. Br J
Cancer. 85:1153–1156. 2001. View Article : Google Scholar : PubMed/NCBI
|
